Nhung N V, Hoa N B, Sy D N, Hennig C M, Dean A S
National Tuberculosis Programme Viet Nam, Hanoi, Viet Nam; Viet Nam Association for Tuberculosis and Lung Disease, Hanoi, Viet Nam.
National Tuberculosis Programme Viet Nam, Hanoi, Viet Nam; Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France.
Int J Tuberc Lung Dis. 2015 Jun;19(6):670-5. doi: 10.5588/ijtld.14.0785.
Viet Nam's Fourth National Anti-Tuberculosis Drug Resistance Survey was conducted in 2011.
To determine the prevalence of resistance to the four main first-line anti-tuberculosis drugs in Viet Nam.
Eighty clusters were selected using a probability proportion to size approach. Drug susceptibility testing (DST) against the four main first-line anti-tuberculosis drugs was performed.
A total of 1629 smear-positive tuberculosis (TB) patients were eligible for culture. Of these, DST results were available for 1312 patients, including 1105 new TB cases, 195 previously treated TB cases and 12 cases with an unknown treatment history. The proportion of cases with resistance to any drug was 32.7% (95%CI 29.1-36.5) among new cases and 54.2% (95%CI 44.3-63.7) among previously treated cases. The proportion of multidrug-resistant TB (MDR-TB) cases was 4.0% (95%CI 2.5-5.4) in new cases and 23.3 (95%CI 16.7-29.9) in previously treated cases.
The fourth drug resistance survey in Viet Nam found that the proportion of MDR-TB among new and previously treated cases was not significantly different from that in the 2005 survey. The National TB Programme should prioritise the detection and treatment of MDR-TB to reduce transmission of MDR-TB in the community.
越南第四次全国结核病耐药性调查于2011年开展。
确定越南对四种主要一线抗结核药物的耐药率。
采用按规模大小概率抽样法选取80个群组。对四种主要一线抗结核药物进行药敏试验（DST）。
共有1629例涂片阳性肺结核患者符合培养条件。其中，1312例患者有药敏试验结果，包括1105例新发病例、195例既往治疗过的病例和12例治疗史不明的病例。新发病例中对任何一种药物耐药的比例为32.7%（95%置信区间29.1 - 36.5），既往治疗过的病例中为54.2%（95%置信区间44.3 - 63.7）。新发病例中耐多药结核病（MDR-TB）的比例为4.0%（95%置信区间2.5 - 5.4），既往治疗过的病例中为23.3%（95%置信区间16.7 - 29.9）。
越南第四次耐药性调查发现，新发病例和既往治疗过的病例中耐多药结核病的比例与2005年调查结果相比无显著差异。国家结核病规划应优先开展耐多药结核病的检测和治疗，以减少社区中耐多药结核病的传播。
